Florfenicol (Nuflor, Resflor Gold)

Florfenicol is a broad-spectrum phenicol antibiotic specifically developed for veterinary use in food-producing animals, representing a significant advancement over its predecessor chloramphenicol due to its improved safety profile and lack of bone marrow toxicity concerns. This synthetic fluorinated derivative works by inhibiting bacterial protein synthesis through binding to the 50S ribosomal subunit, preventing peptide bond formation and effectively halting bacterial growth. The drug demonstrates excellent tissue penetration and achieves therapeutic concentrations in the respiratory tract, making it particularly valuable for treating pneumonia and other respiratory infections in cattle and swine.

The mechanism of action of florfenicol involves reversible binding to the bacterial ribosome, which disrupts the translation process essential for bacterial survival and replication. At typical therapeutic concentrations, florfenicol acts as a bacteriostatic agent, meaning it inhibits bacterial growth without directly killing the organisms, allowing the host immune system to clear the infection. However, at higher concentrations achieved in certain tissues, the drug may exhibit bactericidal properties against susceptible organisms. This dual action makes florfenicol particularly effective against the common respiratory pathogens affecting livestock, including Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni.

Florfenicol is available in several formulations designed to meet different treatment scenarios and species requirements in farm animal practice. The most commonly used preparation is an injectable solution formulated for intramuscular or subcutaneous administration in cattle, with concentrations typically ranging from 300 mg/mL for standard formulations to higher concentrations for extended-release products. Resflor Gold combines florfenicol with flunixin meglumine, providing both antibiotic and anti-inflammatory effects in a single injection. For swine, oral formulations are available that can be administered through drinking water, allowing for treatment of larger groups of animals simultaneously.

From a regulatory standpoint, florfenicol holds FDA approval for use in cattle and swine in the United States, with specific labeled indications for respiratory disease treatment and control. The drug requires a valid veterinary prescription and must be used under the supervision of a licensed veterinarian with an established veterinarian-client-patient relationship. Strict withdrawal times must be observed before animals can enter the food chain, reflecting the regulatory emphasis on food safety and residue avoidance that governs all pharmaceutical use in food-producing animals.

The primary labeled indication for florfenicol in cattle is the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. Bovine respiratory disease complex represents one of the most economically significant health challenges in beef and dairy operations, causing substantial losses through mortality, reduced weight gain, and increased treatment costs. Florfenicol's excellent penetration into respiratory tissues and broad spectrum of activity against the key BRD pathogens make it a first-line treatment option for this condition. The drug is particularly valuable in feedlot settings where respiratory disease outbreaks can spread rapidly through groups of cattle.

In cattle, florfenicol also carries labeled approval for the treatment of infectious bovine keratoconjunctivitis, commonly known as pinkeye, caused by Moraxella bovis. This painful eye condition causes significant economic losses and welfare concerns in beef herds, particularly during summer months when face fly populations peak. Additionally, florfenicol is approved for treating interdigital phlegmon, or foot rot, caused by Fusobacterium necrophorum and Porphyromonas levii. Foot rot causes lameness and reduced productivity, and florfenicol's systemic distribution allows it to reach therapeutic concentrations in the affected tissues of the foot.

Swine respiratory disease represents another major indication for florfenicol use, with the drug approved for treating bacterial pneumonia associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Salmonella choleraesuis, and Streptococcus suis. The oral formulation available for swine allows for convenient mass medication through drinking water systems, making it practical to treat entire groups of pigs during disease outbreaks. This route of administration is particularly valuable in modern swine production facilities where handling individual animals for injection would be impractical and stressful.

Beyond its direct therapeutic applications, florfenicol may be used for metaphylaxis, or the treatment of at-risk animals before clinical signs appear, in situations where BRD is expected to occur. This approach is common in newly arrived feedlot cattle that have experienced the stress of transportation, commingling, and environmental changes that predispose them to respiratory disease. Metaphylactic use must be carefully considered within the context of antimicrobial stewardship principles, reserving such applications for situations where disease occurrence is highly predictable based on historical patterns and risk assessment.

Extra-label use of florfenicol may occur in other food animal species under the guidance of a veterinarian and in compliance with the Animal Medicinal Drug Use Clarification Act (AMDUCA). Such uses must be supported by a valid VCPR and documented appropriately, with extended withdrawal times calculated to ensure food safety. Veterinarians may consult the Food Animal Residue Avoidance Databank (FARAD) for guidance on appropriate withdrawal periods when using florfenicol in an extra-label manner.

The standard dosing regimen for florfenicol in cattle varies depending on the formulation and route of administration chosen. For the conventional injectable formulation (Nuflor), the recommended dose is 20 mg/kg body weight administered intramuscularly, repeated at 48-hour intervals for a total of two treatments. Alternatively, a single subcutaneous injection of 40 mg/kg may be administered, which provides extended drug exposure and eliminates the need for a second handling of animals. The subcutaneous route is preferred by many practitioners because it reduces injection site lesions in valuable muscle tissue and simplifies the treatment protocol.

Resflor Gold, the combination product containing florfenicol and flunixin meglumine, is administered as a single subcutaneous injection at a dose providing 40 mg/kg florfenicol and 2.2 mg/kg flunixin. This combination offers the advantage of providing antibiotic therapy alongside anti-inflammatory and antipyretic effects in a single treatment, addressing both the infection and the inflammatory response that contributes to clinical signs. The convenience of single-dose therapy reduces animal handling, minimizes stress, and improves treatment compliance in busy feedlot operations.

Proper injection technique is essential for achieving optimal therapeutic outcomes and minimizing adverse reactions at injection sites. Subcutaneous injections should be administered in the neck region, using appropriate needle gauge and length for the animal's size. The injection volume should be limited to 10 mL per site in adult cattle to promote absorption and reduce tissue reaction. For intramuscular injections, the neck muscles are the preferred site, avoiding the hindquarters where injection site lesions could affect valuable cuts of meat. Rotating injection sites when multiple treatments are needed helps prevent cumulative tissue damage.

In swine, florfenicol is typically administered orally through medicated drinking water at a dose of approximately 10 mg/kg body weight per day for five consecutive days. The water medication system must be properly calibrated to deliver the correct drug concentration based on water consumption estimates, which can vary with ambient temperature, diet, and health status of the pigs. Careful attention to water line management ensures even drug distribution and prevents under- or overdosing of individual animals within the group.

Treatment duration is an important consideration for achieving therapeutic success while supporting antimicrobial stewardship goals. For bovine respiratory disease, the two-dose intramuscular regimen provides approximately 72 to 96 hours of therapeutic coverage, while the single-dose subcutaneous protocol offers similar duration through the extended-release characteristics of the higher concentration formulation. Veterinary judgment should guide decisions about the need for additional treatment in animals that fail to respond adequately to the initial therapy course.

Withdrawal times for florfenicol must be strictly observed to ensure that meat from treated animals does not contain violative residues. For cattle treated with the standard injectable formulations, the meat withdrawal time is 28 days following the last treatment when administered according to label directions. For swine receiving oral medication through drinking water, the withdrawal period is typically 16 days. These withdrawal times represent the minimum period required under normal use conditions; extra-label use or deviations from labeled dosing may require extended withdrawal periods as determined by FARAD consultation. Florfenicol is not approved for use in dairy cattle of breeding age or in veal calves, and it must never be used in animals whose milk is intended for human consumption.

Florfenicol is generally well-tolerated in cattle and swine when administered according to label directions, with most adverse effects being mild and transient in nature. The most commonly observed side effect is decreased feed consumption, which typically occurs within the first few days following treatment and resolves spontaneously as the drug is cleared from the animal's system. This temporary inappetence is usually mild and does not significantly impact overall animal performance, though it should be monitored in animals that are already compromised by illness or environmental stressors.

Injection site reactions represent the most frequent local adverse effect associated with florfenicol administration in cattle. These reactions may include transient swelling, firmness, and occasional discoloration at the injection site, particularly when the intramuscular route is used. The severity of injection site lesions varies with injection volume, technique, and individual animal factors. Subcutaneous administration generally produces less severe tissue reactions than intramuscular injection, which is one reason the subcutaneous route is often preferred for florfenicol administration. In market animals, residual injection site blemishes may result in trim loss at slaughter, representing an economic consideration in treatment decisions.

Gastrointestinal disturbances may occur in some animals following florfenicol treatment, manifesting as loose feces or diarrhea. This effect is more commonly noted in young animals and those receiving oral formulations, where higher drug concentrations in the gastrointestinal tract can disrupt normal microbial populations. The diarrhea is typically self-limiting and resolves without specific treatment once drug administration is discontinued. Maintaining adequate hydration and monitoring affected animals for signs of dehydration is advisable during the treatment period.

Serious adverse effects from florfenicol are uncommon when the drug is used appropriately, but practitioners should be aware of potential complications. Cardiovascular effects including increased heart rate and changes in blood pressure have been reported in some animals, particularly at doses exceeding label recommendations. Neurological signs such as ataxia or incoordination are rare but have been observed in cases of overdose or accidental exposure. Animals exhibiting unexpected reactions to florfenicol treatment should be evaluated promptly, and supportive care should be provided as indicated.

Species-specific toxicity considerations are important when using florfenicol in farm animal practice. Unlike chloramphenicol, florfenicol does not cause the irreversible bone marrow aplasia that led to chloramphenicol's prohibition in food animals. However, florfenicol is prohibited for use in turkeys due to species-specific sensitivity that can cause mortality. Similarly, the drug should not be used in laying hens producing eggs for human consumption. Cattle treated with florfenicol may experience temporary decreases in reproductive parameters, and the drug is not recommended for use in breeding bulls or during certain stages of gestation without veterinary assessment of the risk-benefit ratio.

Florfenicol is contraindicated in cattle that are producing milk for human consumption, as no withdrawal time has been established for milk and residues could pose food safety concerns. This prohibition applies to all dairy cattle of breeding age, regardless of their current lactation status, to prevent any possibility of drug residues entering the milk supply. Beef cattle that are being raised for meat production are appropriate candidates for florfenicol therapy, provided the required meat withdrawal times are observed before slaughter.

The use of florfenicol is strictly prohibited in turkeys due to species-specific sensitivity that can result in fatal reactions. This contraindication reflects fundamental differences in how different avian species metabolize and respond to phenicol antibiotics. Other poultry species such as chickens may tolerate florfenicol in some circumstances, but veterinary guidance is essential, and the drug is not approved for use in any poultry species in the United States. Laying hens producing eggs for human consumption must never receive florfenicol treatment.

Animals with known hypersensitivity to florfenicol or other phenicol antibiotics should not receive this medication. While allergic reactions to florfenicol are uncommon, prior adverse reactions should be documented and considered before treatment decisions are made. Cross-sensitivity with other phenicol antibiotics may exist, so animals that have reacted to related compounds should be treated with alternative antimicrobials. Signs of hypersensitivity may include urticaria, facial swelling, respiratory distress, or anaphylaxis, any of which warrants immediate discontinuation of therapy and appropriate emergency treatment.

Florfenicol should not be used in breeding bulls intended for reproductive purposes, as studies have shown transient effects on sperm production and quality following treatment. These effects appear to be reversible, but the drug's impact on male fertility makes it unsuitable for use in valuable breeding animals during active service periods. Similarly, while florfenicol is not absolutely contraindicated in pregnant animals, its use during pregnancy should involve careful consideration of potential risks, and alternative treatments should be explored when available. Veal calves represent another prohibited population, as regulatory restrictions prevent florfenicol use in this category of cattle regardless of the clinical situation.

Florfenicol may interact with other antimicrobial agents in ways that can either enhance or diminish therapeutic efficacy. Concurrent use with other bacteriostatic antibiotics that act on the ribosome, such as macrolides (tylosin, tilmicosin) and tetracyclines, may result in antagonistic effects due to competition for binding sites on the bacterial ribosome. When both drug classes bind to overlapping sites on the 50S ribosomal subunit, the combined effect may be less than that achieved by either drug alone. Veterinarians should consider this potential antagonism when designing treatment protocols for complex infections that might otherwise warrant combination therapy.

The combination product Resflor Gold contains flunixin meglumine alongside florfenicol, creating an intentional drug interaction that provides synergistic therapeutic benefits. Flunixin's anti-inflammatory and antipyretic effects complement florfenicol's antibacterial activity, addressing both the infection and the host inflammatory response. However, this combination means that additional NSAID administration should be avoided to prevent the risks associated with NSAID stacking, including gastrointestinal ulceration, renal toxicity, and prolonged bleeding times. The flunixin component also has its own withdrawal requirements that must be considered in food safety planning.

Ionophore antibiotics represent a critically important interaction consideration in cattle and poultry production, though the direct interaction between florfenicol and ionophores is less pronounced than with some other antimicrobial classes. Ionophores such as monensin, lasalocid, and salinomycin are commonly included in feed for growth promotion and coccidiosis prevention. While florfenicol itself does not typically cause the dramatic potentiation of ionophore toxicity seen with some drugs, comprehensive medication reviews should document all compounds an animal is receiving to identify any potential interaction risks.

Vaccine interactions should be considered when scheduling florfenicol treatments in relation to vaccination programs. Bacteriostatic antibiotics may theoretically interfere with the immune response to live bacterial vaccines by inhibiting the replication necessary for vaccine organisms to stimulate immunity. While this interaction is generally more significant with prolonged antibiotic courses, prudent practice suggests separating florfenicol treatment from vaccination when possible, or using killed vaccines in animals receiving antibiotic therapy. Modified live viral vaccines are generally not affected by antibacterial therapy, but overall immune function in sick animals may compromise vaccine response regardless of concurrent medications.

Human safety precautions are essential when handling florfenicol products, as the drug may be irritating to skin, eyes, and mucous membranes. Personnel administering florfenicol should wear appropriate protective equipment including gloves and safety glasses, and should wash hands thoroughly after handling the medication. Direct contact with the injectable solution should be avoided, and any skin exposure should be washed immediately with soap and water. Individuals with known hypersensitivity to florfenicol or other phenicol antibiotics should not handle the product, as allergic reactions including contact dermatitis may occur in sensitized individuals.

Food safety and residue avoidance represent paramount concerns when using florfenicol in food-producing animals. The established withdrawal times must be strictly observed, and treated animals must be clearly identified to prevent premature entry into the food supply. Records of treatment including animal identification, date, dose, route, and calculated withdrawal date should be maintained as part of good production practices and to satisfy regulatory requirements. When animals must be culled before the withdrawal period has elapsed, consultation with regulatory authorities regarding condemnation procedures is necessary.

Environmental considerations include proper disposal of unused medication, used syringes, and empty containers. Florfenicol should not be disposed of through wastewater systems or in locations where it could contaminate water supplies. Pharmaceutical waste should be handled according to local regulations, which may require use of approved pharmaceutical disposal services. The environmental persistence of florfenicol and its potential impact on soil and water microorganisms make responsible disposal an important aspect of sustainable livestock production practices.

Antimicrobial resistance stewardship demands judicious use of florfenicol to preserve its efficacy for future generations of food animals. The drug should be used only when a bacterial infection is present or highly likely, and treatment should follow labeled directions or documented extra-label protocols developed by a veterinarian. Diagnostic testing to confirm bacterial involvement and identify the causative organism supports targeted therapy and helps avoid unnecessary antibiotic use. Treatment failures should prompt reassessment of the diagnosis, consideration of antimicrobial susceptibility testing, and evaluation of management factors that may be contributing to disease persistence.

Special precautions apply to certain animal populations beyond those with absolute contraindications. Debilitated animals, those with significant liver or kidney compromise, and very young animals may metabolize and eliminate florfenicol differently than healthy adult animals. Dose adjustments may be necessary in these populations, and extended monitoring for adverse effects is advisable. Additionally, animals under significant stress from transportation, environmental extremes, or concurrent disease may be more susceptible to adverse effects and should be monitored closely during treatment.

Florfenicol injectable solutions should be stored at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F), protected from light and freezing. The products maintain stability under these conditions until the expiration date printed on the container. Exposure to extreme temperatures during storage or transport may affect product integrity, so proper cold chain management is important when products are shipped during summer or winter months. Visual inspection of the solution before use can identify products that may have been compromised, as precipitation, color changes, or particulate matter indicate deterioration.

Multi-dose vial handling requires attention to aseptic technique to prevent contamination that could affect product stability or cause injection site infections. The rubber stopper should be cleaned with alcohol before each needle insertion, and sterile needles should be used for each withdrawal from the vial. Once a multi-dose vial has been punctured, the in-use shelf life may be shorter than the original expiration date, and manufacturer recommendations for maximum duration of use after first puncture should be followed. Drawing up medication into syringes ahead of time is not recommended, as the drug may interact with syringe components or lose sterility during storage.

Proper disposal of pharmaceutical waste is both a regulatory requirement and an environmental responsibility. Unused or expired florfenicol should not be poured down drains or disposed of in regular trash where it could enter water supplies or landfills. Many veterinary practices utilize pharmaceutical take-back programs or licensed waste disposal services to ensure proper handling of expired medications. Empty containers that held florfenicol products should be rinsed thoroughly and disposed of according to label directions, which may specify puncturing or otherwise rendering the container unusable to prevent repurposing. Documentation of disposal activities supports regulatory compliance and demonstrates commitment to responsible pharmaceutical stewardship.

Cattle breeds show some variation in their response to florfenicol therapy, though these differences are generally related to body composition and production type rather than breed-specific pharmacological sensitivities. Beef cattle breeds with higher muscle mass may experience more significant injection site reactions when intramuscular administration is used, as larger injection volumes are sometimes needed for heavier animals. Subcutaneous administration helps minimize this concern across all beef breeds. In contrast, dairy breeds, while prohibited from receiving florfenicol during milk production, may be treated during the dry period with appropriate veterinary supervision and extended withdrawal calculations.

Producton type significantly influences florfenicol use decisions in cattle operations. Feedlot cattle represent the most common recipients of florfenicol therapy due to the high incidence of bovine respiratory disease in this production setting. The stress of weaning, transportation, commingling, and dietary transition creates conditions favorable for respiratory pathogen establishment. Cow-calf operations may use florfenicol less frequently, but the drug remains valuable for treating individual cases of respiratory disease, pinkeye, or foot rot in breeding herds. Stocker cattle operations face similar disease challenges to feedlots and frequently incorporate florfenicol into treatment protocols.

Swine breed considerations are less prominent than species-specific factors, as modern commercial swine production involves relatively uniform genetics within production systems. However, management factors such as facility type, group size, and production stage influence how florfenicol is used in swine. Nursery pigs are frequent recipients of water-medicated florfenicol when respiratory disease outbreaks occur, while finishing pigs and breeding stock face different risk profiles. Breeding animals require careful attention to withdrawal times if they may enter the food chain, and reproductive performance should be monitored in animals receiving treatment during breeding periods.

Age and weight considerations affect dosing accuracy and drug distribution across all species receiving florfenicol. Young animals have different body composition, metabolic rates, and organ function compared to adults, potentially affecting drug pharmacokinetics. Accurate weight estimation is essential for proper dosing, as underdosing promotes treatment failure and resistance development while overdosing increases adverse effect risk and withdrawal time uncertainty. For group treatments through water medication in swine, variations in water consumption among individual pigs of different sizes within a group create inherent challenges in achieving uniform dosing across the population.

Within the phenicol antibiotic class, chloramphenicol was the original compound from which florfenicol was derived. However, chloramphenicol is prohibited for use in food-producing animals due to concerns about irreversible aplastic anemia in humans exposed to residues. This prohibition led to the development of florfenicol as a safer alternative that maintains the antimicrobial spectrum of chloramphenicol while eliminating the bone marrow toxicity risk. Thiamphenicol is another phenicol derivative used in some countries, though its availability and regulatory status vary by region and it lacks FDA approval in the United States for food animals.

Alternative antimicrobials for bovine respiratory disease include several drug classes with different mechanisms of action. Macrolide antibiotics such as tulathromycin (Draxxin), tilmicosin (Micotil), and gamithromycin (Zactran) are commonly used for BRD treatment and prevention, offering convenient single-dose therapy with extended duration of action. Tetracyclines including oxytetracycline provide broad-spectrum coverage and remain economical options for respiratory disease treatment. Fluoroquinolones such as enrofloxacin (Baytril) and danofloxacin (Advocin) offer bactericidal activity against respiratory pathogens but face increasing scrutiny regarding resistance concerns and are reserved for specific clinical situations.

Combination products and alternative formulations expand the therapeutic options available for managing respiratory and other infections in food animals. Resflor Gold represents a combination approach by including the NSAID flunixin meglumine with florfenicol, providing anti-inflammatory benefits alongside antibiotic therapy. Potentiated sulfonamide combinations such as trimethoprim-sulfadoxine offer an alternative drug class for respiratory infections when phenicols or other first-line agents are unsuitable. When selecting among these alternatives, veterinarians consider factors including bacterial susceptibility patterns, treatment history, withdrawal time requirements, and cost-effectiveness within the context of each operation's disease management program.